Impact of Mangankang Pill on Cellular Immune Function to Patients with Liver Stagnation and Spleen Deficiency Syndrome in Chronic Hepatitis B

Abstract:

Objective: Observed the impact of Mangankang pill to the patients with liver stagnation and spleen deficiency syndrome in chronic hepatitis B(CHB) cellular immune function. Method: Seventy-one patients with chronic hepatitis B were enrolled and randomized into two groups:the treated group(36 cases)and the control group(35 cases).The two groups were given lamivudine treatment,the treatment group was given Mangankang pill,6 g/times, 3 times/day, with a course of eight weeks. Result: The two groups can improve liver pain or discomfort, anorexia,fatigue, bloating symptoms,the treatment group better than the control group(P<0.05).No significant difference between the two groups in the improvement of alanine aminotrans ferase(ALT) and aspartate aminotrans ferase(AST).The treatment group was more significant in the reduction of hepatitis B virus(HBV)-DNA (P<0.05).Treatment group CD3⁺,CD4⁺ increased,CD8 decreased,CD4⁺/CD8⁺ increased after treatment.Differencebwas statistically significant compared with the controlngroup(P<0.05). Conclusion: Mangankang pill can improve the status of liver stagnation and spleen deficiency syndrome in patients with chronic hepatitis B-free cellular immune disorders, improve the therapeutic effect of anti-viral.